ArticleCommunications medicine2025
Personalised bactericidal combination regimens against carbapenem-resistant Pseudomonas aeruginosa.
Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Characterization and comparative genomic analysis of a novel bacteriophage against an extremely drug-resistantMicrobiology spectrum · 2026Article
- Predictors of Mortality inPathogens (Basel, Switzerland) · 2026Review
- Broad-Spectrum Protective Efficacy of a Fully Human Antibody Cocktail Targeting PcrV, ETA, and PA0833 AgainstInfection and drug resistance · 2026Article
- Uncovering the Hidden Diversity and Antimicrobial Resistance of Uropathogens in a Tertiary-Care Hospital in Bangladesh.International journal of microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundLimited treatment options are available for carbapenem-resistant Pseudomonas aeruginosa (CRPA), especially those harbouring carbapenemases. Given the variability in effectiveness of antibiotic combinations, in vitro test-guided antibiotic therapies have been suggested to improve the outcomes of patients receiving combination therapy. We investigated the in vitro bactericidal activities of various combinations against CRPA and described our experience of using a personalised test-guided approach in managing these difficult-to-treat infections.
methodsIn vitro antibiotic combination tests (iACTs) comprising up to 180 unique combinations at clinically relevant unbound concentrations were performed for CRPA isolates collected for a monocentric prospective cohort study conducted between 2017 and 2022.
resultsIn vitro activities of antibiotic combinations are highly strain-specific. Polymyxin-containing combinations exhibit the highest bactericidal activity [454/497 (91%) isolate-combination pairs] against 66 isolates tested. Most of the CRPA produce carbapenemases (73%). Polymyxin-sparing combinations exhibiting >60% bactericidal activity include fosfomycin + aztreonam (40/58) and fosfomycin + cefepime (37/58). We show good outcomes in the 42 patients who eventually received at least 72 h of personalised iACT-guided therapy [end-of-treatment clinical response rate: 93%; 30-day all-cause mortality: 2%]. We observe microbiological eradication for all bloodstream infections, but 13% of patients get reinfected with CRPA subsequently.
conclusionsPolymyxin-containing combinations exhibit the highest bactericidal activity against CRPA, while fosfomycin + aztreonam or fosfomycin + cefepime represent promising polymyxin-sparing options. A personalised in vitro test-guided treatment approach may be feasible for managing P. aeruginosa infections, particularly those involving carbapenemase production and/or difficult-to-treat phenotypes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.